VectorY raises $83.5 million to advance experimental neurodegenerative-disease therapies

On November 11, 2026, Amsterdam-based VectorY Therapeutics announced €74.5 million ($83.5 million) in new financing to advance its antibody gene-therapy pipeline for neurodegenerative diseases.

The financing adds to the company’s Series A. New participants include Angelini Ventures, Invest-NL, and the European Investment Bank (EIB); returning backers include Forbion, EQT Life Sciences, MRL Ventures, Insight Partners, BioGeneration Ventures, Eli Lilly, and the ALS Investment Fund.

A €30 million EIB convertible loan is part of the financing and is supported by the European Commission’s InvestEU program.

The main funding priority is VTx-002, VectorY’s experimental ALS therapy, through milestones in the PIONEER-ALS Phase 1/2 study, including its final readout. The trial is evaluating safety, tolerability, and preliminary activity; it is not yet established that the therapy works.

VTx-002 uses a viral vector to deliver genetic instructions so cells in the central nervous system can produce an antibody targeting abnormal TDP-43, a protein implicated in ALS. The approach aims to provide sustained antibody production after a single administration.

The company says funding will also support VTx-003 for Huntington’s disease and earlier programs for frontotemporal dementia and Alzheimer’s disease. These remain investigational.